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Abstract	
Tumor	spheroids	are	a	3-D,	 in	vitro	tumor	model	that	holds	promise	for	testing	cancer	therapies	 in	
vitro	using	microfluidic	devices.	Understanding	how	to	 tailor	 the	properties	of	a	 tumor	spheroid	 is	
critical	for	evaluating	a	therapy	over	a	broad	range	of	possible	indications.	We	use	human	cancer	colon	
cells	(HCT-116)	to	produce	tumor	spheroids	with	targeted	diameters	and	demonstrate	the	ability	to	
manipulate	the	microenvironment	of	the	spheroids.	We	further	 investigate	the	flow	field	around	a	
tumor	 spheroid	 contained	 in	 a	 microfluidic	 device,	 and	 show	 the	 effect	 of	 that	 flow	 field	 on	
nanoparticle	accumulation	on	the	perimeter	of	the	tumor	spheroid.		
We	demonstrate	how	to	control	tumor	spheroid	growth	rates	by	varying	the	number	of	cells	initially	
seeded	 into	 microwell	 growth	 chambers.	 Furthermore,	 the	 presence	 of	 a	 necrotic	 core	 in	 the	
spheroids	could	be	controlled	by	changing	the	glucose	concentration	of	the	incubation	medium.	This	
manipulation	had	no	effect	on	the	size	of	the	tumor	spheroids	or	hypoxia	in	the	spheroid	core,	which	
has	been	predicted	by	a	mathematical	model	 in	computer	simulations	of	spheroid	growth.	Control	
over	 the	presence	of	 a	necrotic	 core	while	maintaining	other	physical	parameters	of	 the	 spheroid	
presents	an	opportunity	to	assess	the	impact	of	core	necrosis	on	therapy	efficacy.	
Using	micro-particle	imaging	velocimetry	(micro-PIV),	we	characterize	the	hydrodynamics	and	mass	
transport	 of	 nanoparticles	 in	 tumor	 spheroids	 in	 a	microfluidic	 device.	We	 observe	 a	 geometrical	
dependence	on	the	flow	rate	experienced	by	the	tumor	spheroid	in	the	device,	such	that	the	“front”	
of	the	spheroid	experiences	a	higher	flow	velocity	than	the	“back”	of	the	spheroid.	Using	fluorescent	
nanoparticles,	we	demonstrate	a	heterogeneous	accumulation	of	nanoparticles	at	the	tumor	interface	
that	correlates	with	the	observed	flow	velocities.	The	penetration	depth	of	these	nanoparticles	further	
into	the	tumor	spheroid	is	size	dependent,	consistent	with	reports	in	the	literature.	
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1 Introduction	
Cancers	are	among	the	leading	causes	of	morbidity	and	mortality	worldwide,	with	approximately	14	
million	new	cases	and	8.2	million	cancer	related	deaths	in	2012.	The	number	of	new	cases	per	year	is	
expected	to	rise	by	70%	in	the	next	two	decades	(Stewart	et	al.	2014).	The	failure	to	translate	new	
discoveries	into	actual	therapies	is	due	to	inherent	differences	in	results	found	between	the	treatment	
of	tumors	in	murine	and	other	animal	models	and	actual	human	tumors	(Nichols	and	Bae	2012).	This	
difference	has	led	to	greater	motivation	to	construct	in	vitro	models	that	are	alternatives	to	animal	
models	(Elliott	and	Yuan	2011;	Hirschhaeuser	et	al.	2010;	Ricketts	et	al.	2014;	Theodoraki	et	al.	2015).	
Accurate	 in	vitro	models	for	cancer	therapies	must	capture	the	3-D	microenvironment	of	tumors	 in	
vivo	(Kunz-Schughart	et	al.	2004;	Pampaloni	et	al.	2007).	Key	features	of	the	tumor	microenvironment	
include	hypoxic	and	necrotic	cores,	which	have	been	implicated	in	drug	resistance	observed	in	tumors	
(Elliott	and	Yuan	2011;	Sutherland	1988).	The	presence	of	hypoxia	or	necrosis	in	the	tumor	core	results	
from	nutrient	gradients	 induced	by	reduced	mass	 transport	due	to	 the	 tumor’s	3-D	structure	 (Jain	
1999;	 Sutherland	 1988).	 2-D	 models,	 such	 as	 cell	 monolayers,	 fail	 to	 capture	 these	 types	 of	
phenomena,	and	thus	can	skew	the	efficacy	of	cancer	therapies	(Karlsson	et	al.	2012).	
Tumor	spheroids	are	an	established	3-D	in	vitro	model	of	tumors	that	are	easy	to	produce,	and	can	
achieve	features	like	hypoxic	and	necrotic	cores	at	size	scales	consistent	with	in	vivo	tumors	(Achilli	et	
al.	2012;	Costa	et	al.	2016;	Hirschhaeuser	et	al.	2010;	Ivascu	and	Kubbies	2006;	Ravizza	et	al.	2009;	
Sutherland	1988;	Theodoraki	et	al.	2015;	Wang	et	al.	2014).	Since	the	spheroid	is	a	3-D	structure,	it	
replicates	the	limited	transport	of	blood-borne	nutrients	and	solutes	experienced	in	vivo	by	portions	
of	a	tumor	distant	from	the	vasculature	(Albanese	et	al.	2013a;	Albanese	et	al.	2012;	Cabral	et	al.	2011;	
Raghavan	 et	 al.	 2016).	 Tumor	 spheroids	 also	 offer	 a	 convenient	 platform	 for	 construction	 of	
mathematical	models	 to	describe	cell	proliferation	 (Ambrosi	and	Mollica	2002;	Drasdo	et	al.	2007;	
Drasdo	and	Höhme	2005).	Tumor	spheroids	result	from	the	self-assembly	of	cancer	cells	due	to	cell-
cell	 interactions,	 and	 several	 techniques	 and	 instruments	 have	 been	 developed	 to	 create	 tumor	
spheroids	(Alessandri	et	al.	2013;	Drewitz	et	al.	2011;	Froehlich	et	al.	2016;	Fu	et	al.	2014;	Karlsson	et	
al.	2012;	Mehesz	et	al.	2011;	Ravizza	et	al.	2009;	Santo	et	al.	2016).	While	automated	systems	for	
spheroid	 production	 are	 an	 ongoing	 area	 of	 research,	 there	 remains	 a	 need	 for	 straightforward,	
inexpensive	schemes	to	produce	tumor	spheroids	in	order	for	the	general	research	community	to	have	
access	 to	 these	 in	 vitro	 tumor	models.	 Furthermore,	 understanding	 how	 the	 properties	 of	 tumor	
spheroids,	such	as	diameter	or	the	presence	of	a	necrotic	core,	can	be	manipulated	by	easily	accessible	
conditions	(e.g.,	initial	cell	count	or	nutrient	concentration)	enables	the	in	vitro	investigation	of	tumor	
treatment	therapies	over	a	broader	range	of	tumor	conditions.	
In	addition	 to	preparing	accurate	 in	vitro	models	of	 tumors,	 it	 is	necessary	 to	 replicate	 the	 in	vivo	
environment	 surrounding	 the	 tumor—specifically,	 the	vasculature	system.	Error!	Reference	source	
not	found.a	depicts	a	simplified	view	of	a	tumor	mass	embedded	in	a	capillary	network	(Nichols	and	
Bae	2012;	Sutherland	1988).	Mass	 transport	 from	the	capillary	 into	the	tumor	vasculature	delivers	
nutrients	that	sustain	tumor	growth,	and	provides	a	means	for	delivering	solution-borne	therapeutics	
into	 the	 tumor.	Microfluidic	 devices	 are	 ideally	 suited	 for	 replicating	 the	 scenario	 shown	 in	 Error!	
Reference	source	not	found.a,	due	to	the	ability	to	fabricate	devices	with	channel	dimensions	similar	
to	 the	 human	 vasculature	 system,	 and	 good	 control	 over	 the	 environment	 inside	 of	 the	 device	
(Khademhosseini	 et	 al.	 2006;	 Whitesides	 2006).	 Error!	 Reference	 source	 not	 found.b	 shows	 a	
schematic	of	the	microfluidic	device	used	in	this	study,	which	is	based	on	a	recently	reported	design	
(Albanese	et	al.	2013b).	The	design	of	the	device	allows	the	sequestration	of	a	tumor	spheroid	with	a	
diameter	of	around	400	μm	in	a	region	of	the	device	suitable	for	direct	observation	using	microscopy	
techniques.	The	flow	of	solution-borne	nutrients	and	therapeutics	occur	from	left	to	right,	and	the	
	
	
uptake	of	fluorescent	markers	or	the	response	of	the	tumor	spheroid	to	a	solution-borne	therapeutic	
can	be	tracked	using	standard	microscopy	techniques.	
This	article	examines	two	aspects	of	the	use	of	tumor	spheroids.	The	first	aspect	considers	how	to	
manipulate	 the	properties	of	 the	 tumor	 spheroid,	 in	particular	 the	diameter	and	presence	of	 core	
necrosis.	The	first	set	of	experiments	in	this	work	develops	an	optimized	protocol	for	producing	tumor	
spheroids	 with	 targeted	 diameters	 in	 commonly	 available	 microwell	 plates.	 The	 second	 set	 of	
experiments	 shows	 how	 the	 nutrient	 profile	 of	 the	 incubation	 media	 used	 to	 culture	 the	 tumor	
spheroids	affects	the	microenvironment	within	the	resulting	spheroids.	In	particular,	we	manipulate	
the	presence	of	a	necrotic	 core	 in	a	 tumor	spheroid	by	changing	 the	glucose	concentration	of	 the	
incubation	 media.	 These	 experiments	 show	 how	 the	 tumor	 spheroid	 production	 process	 can	 be	
optimized	to	achieve	tumor	spheroids	with	tailored	properties	for	researchers	who	do	not	have	access	
to	automated	spheroid	growing	systems.	The	results	of	these	experiments	further	allow	us	to	confirm	
experimentally	an	observation	made	in	a	computer	simulation	of	tumor	spheroid	growth	(Drasdo	and	
Höhme	2005),	which	found	that	glucose	concentration	affected	core	necrosis	without	affecting	the	
growth	rate	of	the	tumor	spheroids.		
The	second	set	of	experiments	in	this	article	characterize	the	flow	profile	around	the	tumor	spheroid	
in	the	microfluidic	device	(shown	in	Error!	Reference	source	not	found.b)	using	microparticle	imaging	
velocimetry	 (micro-PIV).	Our	 results	 reveal	a	heterogeneous	 fluid	velocity	profile	 impinging	on	 the	
spheroid,	which	 correlates	with	 a	 heterogeneous	 distribution	 of	 nanoparticle	 accumulation	 at	 the	
spheroid	perimeter.	
2 Materials	and	Methods		
2.1 Media	Preparation	
2.1.1 Cell	culture	medium		
DMEM	with	phenol	red	containing	4.5	g/L	glucose	(high	glucose)	or	1	g/L	glucose	(low	glucose),	110	
mg/mL	 sodium	 pyruvate,	 584	 mg/L	 L-glutamine	 and	 3.7	 g/L	 NaHCO3	 (Life	 Technologies	 cat.	 nos.	
11995065	 &11885-084),	 supplemented	 with	 100	 U/ml	 penicillin,	 100	 mg/ml	 streptomycin	 (Life	
Technologies,	cat.	no.	15070063),	and	10	v%	Fetal	Bovine	Serum	(Life	Technologies,	cat.	no.	12483020)	
was	used	as	a	standard	medium	for	cell	and	spheroid	culturing. 
2.1.2 Imaging	medium		
An	aqueous	solution	of	2	g/L	bovine	serum	albumin,	125mM	NaCl,	5.7mM	KCl,	2.5mM	CaCl2,	1.2mM	
MgCl2,	10mM	HEPES	at	pH	7.4	was	used	as	a	standard	imaging	medium	for	microscopy	analysis	of	
spheroids	(Albanese	et	al.	2013a).	
2.2 Spheroid	Culturing	and	Analysis	
2.2.1 Cancer	cell	culture		
Colon	HCT116,	Lung	A549	and	Glioblastoma	U87MG	cancer	cells	were	obtained	by	generous	donation	
from	Cell	 Signal	 Unit	 at	OIST.	 Cells	were	 seeded	 in	 typical	 plastic	 bottom	 flasks	 (Corning,	 cat.	 no.	
CLS430641),	maintained	in	cell	culture	medium	(see	above)	and	incubated	under	typical	cell	culture	
conditions	at	37°C,	5%	CO2	in	humidified	incubators.	Routine	passaging	of	colon	cancer	cells	(HCT116)	
was	 performed	 every	 3-4	 days	 by	 detaching	 cells	 with	 Accutase	 (Nacalai	 cat.	 no.	 12679-54)	 and	
reseeding	at	1:10	(3	days)	or	1:25	(4	days)	dilutions.	
	
	
2.2.2 Spheroid	culture	plate	preparation	
To	prevent	cell	attachment	either	agarose	or	poly(2-hydroxyethyl	methacrylate)	(PHEMA)	were	used	
to	coat	96-well	plates.	Agarose	coating	was	conducted	as	previously	reported	(Friedrich	et	al.	2009).	
Briefly,	coating	was	performed	2	hours	before	cell	seeding	by	adding	50	µL	of	15	g/L	agarose	in	cell	
culture	medium	to	flat-bottomed	wells.	The	15	g/L	agarose	solution	preparation	procedure	typically	
consisted	in	adding	agarose	powder	(Sigma	cat.	No.	A9539)	to	culture	medium,	autoclaving	20	min	at	
120°C	to	dissolve	the	powder	and	directly	transferring	and	maintaining	the	solution	in	a	70°C	water	
bath	during	dispensing	to	avoid	the	solution	hardening.	After	dispensing,	agarose	hardened	in	wells	
in	 seconds	 to	minutes,	 forming	 a	 concave	 bed	 for	 cells.	 PHEMA	 coating	was	 performed	 in	 round-
bottom	wells	 by	dispensing	50	µL	20	 g/L	PHEMA	 in	95	 v%	EtOH	and	air	 drying	overnight	 at	 room	
temperature,	producing	a	thin	homogeneous	film	coating.	The	20	g/L	PHEMA	solution	was	prepared	
by	dissolving	PHEMA	powder	(Sigma	cat.	no.	P3938)	in	a	95	v%	EtOH	aqueous	solution	overnight	in	a	
tightly	sealed	beaker,	heated	at	80°C	with	agitation.	
2.2.3 Cancer	cell	spheroid	seeding	
Colon	cancer	cells	grown	as	a	monolayer	were	detached	with	Accutase	and	200	µL	of	the	cell	solution	
containing	500-2000	cells	were	distributed	into	single	wells	of	96	well	plates	pre-coated	with	either	
agarose	or	PHEMA	(refer	to	Spheroid	culture	plate	preparation	above).	Plates	were	then	centrifuged	
5	min	at	1000	rpm	using	a	swinging	bucket	Eppendorf	Centrifuge	(Eppendorf	AG)	and	incubated	under	
typical	 cell	 culture	 conditions	 at	 37°C,	 5%	 CO2	 in	 humidified	 incubators.	 By	 day	 3	 of	 culture,	 cells	
formed	into	compact	spheroids	and	were	analyzed.	
2.2.4 Spheroid	size	and	quality	analysis		
Spheroid	size	was	analyzed	in	ImageJ	by	fitting	an	ellipse	to	the	spheroid	images	captured	by	phase	
contrast	microscopy	(Olympus	SZX7	upright	microscope).	Spheroid	diameter	was	then	defined	as	the	
quadratic	mean	of	the	small	and	 large	ellipse	diameters.	Spheroids	were	defined	of	good	quality	 if	
they	showed	good	signs	of	compactness	and	no	clear	irregularities	in	their	circularity.	Some	examples	
of	both	properly	formed	and	poorly	formed	spheroids	are	shown	in	Figure	S1.	
2.3 Cell	Staining	Protocols	
2.3.1 Histological	staining	
Spheroids	were	fixed	in	4	v%	paraformaldehyde	(PFA)	in	Phosphate	Buffer	Saline	(PBS)	for	1	hour	at	
room	temperature.	The	PFA	solution	was	prepared	fresh	two	hours	prior	to	fixing	by	dissolving	PFA	
powder	(Sigma	P6148)	in	PBS	(Nacalai	cat.	no.	14249-24)	heated	at	80°C	with	thorough	agitation.	The	
fixed	spheroids	were	then	individually	embedded	in	OCT	Compound	(Sakura	Finetek,	cat.	no.	4583),	
placed	in	cryomolds	(Sakura	Finetek,	cat.	no.	4728)	and	snap	frozen	at	the	interface	of	liquid	nitrogen	
on	 floating	 aluminium	 foil	 boats.	 Frozen	 samples	were	 stored	 at	 -80°C	 and	 then	 transferred	 to	 a	
cryostat	(Leica	CM3050s)	for	sectioning	where	10	µm	sections	of	the	spheroid	were	cut,	retrieved	on	
MAS-coated	 glass	 slides	 (Matsunami,	 cat.	 no.	 S9441)	 and	 air	 dried	 overnight.	 Finally,	 histological	
staining	was	performed	following	the	protocol	previously	described	(Ellis),	with	the	slight	difference	
that	the	eosin	was	prepared	in	aqueous	form	and	that	the	mounting	medium	used	was	aqueous-based,	
thus	avoiding	any	dehydration	steps.	
2.3.2 Hypoxia	immunostaining		
Spheroids	were	cryosectioned	in	the	same	way	as	for	histological	staining	with	the	slight	difference	
that	spheroids	were	incubated	with	pimonidazole	prior	to	fixation	and	sectioned	at	a	5	µm	thickness.	
Briefly,	a	4	mM	pimonidazole	in	PBS	stock	was	prepared	from	pimonidazole	powder	(Hypoxyprobe,	
cat.	no.	HP2-100)	and	added	to	spheroids	at	a	final	concentration	of	200	µM,	followed	by	a	1	hour	
incubation	in	a	humidified	incubator	at	37°C,	5%	CO2.	Typical	immunostaining,	as	previously	described	
	
	
(Aguilera	and	Brekken	2014),	was	then	performed	against	pimonidazole	to	reveal	hypoxic	regions	by	
the	use	of	mouse	FITC-conjugated	IgG1	monoclonal	antibodies	(clone	4.3.11.3)	(Hypoxyprobe,	cat.	no.	
HP2-100).	Following	immunostaining,	sample	nuclei	were	counterstained	for	15	min	with	0.5	µg/mL	
Hoechst	(Sigma,	cat.	no.	H6024).	Finally,	slides	were	mounted	and	a	coverslip	was	placed	on	top	of	
the	slide,	and	observed	by	fluorescence	microscopy	(Zeiss	LSM510	inverted	microscope).	
2.3.3 Spheroid	live-dead	cell	imaging	
Calcein-AM	(Nacalai,	cat.	no.	06735-81)	and	Propidium	Iodide	(Nacalai,	cat.	no.	29037-76)	were	used	
for	 live	 cell	 and	 dead	 cell	 staining	 respectively.	 Calcein-AM	 and	 Propidium	 Iodide	 were	 added	 to	
spheroid	culture	wells	at	final	concentrations	of	10	µg/mL	and	20	µM	respectively	and	incubated	for	
4	hours	at	37°C,	5%	CO2	in	humidified	incubators.	Spheroids	were	then	transferred	in	imaging	medium	
(refer	to	REAGENT	SETUP)	and	seeded	in	glass	slide	chambers	(Nunc,	cat.	no.	177402)	pre-coated	with	
200	µL	of	100	g/L	Bovine	Serum	Albumin	(Sigma,	cat.	no.	A2153)	for	1	hour.	Images	were	captured	by	
confocal	microscopy	(Zeiss	LSM510	confocal	microscope).	
2.4 Microfluidic	Device	Fabrication	and	Characterization	of	Spheroid	Containing	
Devices	
2.4.1 Microfluidic	device	preparation	
Microfluidic	devices	were	fabricated	by	molding	and	crosslinking	PDMS	(Dow	Corning,	Sylgard	184)	on	
an	epoxy	resin	master	previously	produced	by	soft	lithography	in	clean	room	conditions.	The	cured	
PDMS	mold	was	irreversibly	bound	to	a	glass	coverslip	petri	dish	(ibidi,	cat.	no.	81158)	using	oxygen	
plasma	(Harrick,	PDC-001)	followed	by	heating	at	100°C	for	1	hour.	Care	was	taken	to	punch	a	2	mm	
diameter	hole	through	the	PDMS	at	the	device	inlet	to	form	a	well	for	spheroid	seeding,	whereas	the	
outlet	was	connected	to	Tygon	tubing	(BD	Intrimedic,	cat.	no.	427406)	for	later	connection	to	a	syringe	
pump	system	(negative	pressure-driven	flow).	The	microfluidic	device	was	designed	with	a	channel	
height	of	380	µm	in	order	to	slightly	compress	the	400	µm	spheroids	 in	order	to	ensure	adequate	
immobilization	for	imaging.	The	channel	entrance	is	600	µm	wide	and	widens	further	to	1,200	µm	at	
the	imaging	chamber	to	ensure	the	laminar	flow	profile	surrounding	the	spheroids	before	arriving	at	
the	dam	wall	to	minimize	physical	damage.		
2.4.2 Microfluidic	device	flow	field	characterization	by	Micro-Particle	Image	Velocimetry	
(micro-PIV)	
The	microfluidic	device	was	precoated	for	1	hour	with	100	g/L	Bovine	Serum	Albumin	(Sigma,	cat.	no.	
A2153)	followed	by	3	washes	of	imaging	medium	(see	Reagent	Setup	section).	Spheroids	were	then	
loaded	with	gentle,	pressure	driven	flow	of	imaging	medium.	The	device	was	then	mounted	on	the	
micro-PIV	stage	and	a	dilute	solution	of	3.2	µm	fluorescent	polystyrene	beads	in	a	25	v%	glycerol	and	
imaging	 medium	 solution	 was	 flowed	 through	 the	 system.	 Glycerol	 was	 used	 to	 avoid	 particle	
sedimentation,	 and	 did	 not	 visually	 affect	 spheroid	 morphology.	 At	 25	 v%,	 the	 solution	 viscosity	
increased	to	twice	the	viscosity	of	water.	The	micro-PIV	imaging	system	comprises	a	1280	x	800	pixel,	
CMOS	camera	(Phantom	Micro	M310,	Vision	Research	Inc.,	NJ),	an	inverted	microscope	(Nikon	Eclipse	
TE	2000)	and	a	dual-pulsed	Nd:YLF	laser	(Terra	PIV,	Continuum	Inc.,	CA)	emitting	at	527	nm.	A	4x,	NA	
=	0.13	numerical	aperture	objective	attached	to	the	microscope	is	used	to	focus	on	the	midplane	of	
the	tumor	spheroid	contained	in	the	microfluidic	device	viewing	chamber.	Illumination	of	the	focused	
area	by	the	laser	causes	the	fluorescent	microparticles	to	emit	a	longer	wavelength	than	the	excitation	
wavelength.	The	reflected	laser	light	is	filtered	out,	so	that	the	camera	detects	only	the	fluorescent	
microparticles.	The	camera	records	pair	of	images	with	a	pre-defined	time	step	between	each	image	
so	that	the	microparticles	translate	approximately	4	pixels	between	each	image.	The	image	pairs	were	
	
	
analyzed	with	the	standard	cross-correlation	PIV	algorithm	(TSI	Insight	4G	software),	and	the	results	
further	analyzed	in	Tecplot	Focus	software	(Tecplot	Inc.,	WA).	
2.4.3 Nanoparticle	penetration	and	accumulation	assay	
Rhodamine-B	conjugated	polystyrene	beads	(Nanocs	cat.	nos.	PS20-RB,	PS50-RB)	with	20nm	and	50	
nm	diameters	were	characterized	by	dynamic	light	scattering	(Malvern	Zetasizer	Nano	ZS)	prior	to	the	
experiment,	 in	 typical	 experimental	 conditions	 (0.0634%	 (wt/vol)	 in	 imaging	 medium	 at	 37°C).	
Nanoparticle	concentration	was	determined	by	approaching	the	clinical	administration	values	found	
in	literature	(Yanagie	et	al.	2014).	Device	preparation	followed	the	same	protocol	as	that	for	the	micro-
PIV,	specifically	coating	with	Bovine	Serum	Albumin	then	washing	with	 imaging	medium.	Next,	the	
device	was	mounted	on	a	cell	culture	stage	(37°C,	5%	CO2).	Flow	rate	was	controlled	using	a	syringe	
pump	(cetoni	GmbH	neMESYS	low	pressure	syringe	pump),	with	flow	being	driven	by	an	empty	syringe	
applying	negative	pressure	to	the	outlet	and	medium	containing	nanoparticles	replenishing	the	inlet	
well	 at	 an	 equal	 rate.	 Nanoparticle	 accumulation	 images	 were	 taken	 using	 a	 63x	 oil	 immersion	
objective	on	a	ZEISS	LSM780	confocal	microscope.	Images	were	taken	at	three	different	heights	z	=	
{50;75;100	 µm}	 of	 the	 spheroid.	 Fluorescence	 distribution	 was	 analyzed	 with	 a	 Matlab	 program	
developed	 in-house	 that	 localized	 the	 spheroid	 edge	 and	measured	mean	 fluorescence	 at	 various	
depths	throughout	the	spheroid.	Fluorescence	values	were	then	averaged	on	whole	cell	layers	(10	µm	
depth	 radial	 contractions)	 and	 normalized	 to	 the	 fluorescence	 of	 the	 surrounding	 media	 to	 give	
accumulation	values	per	cell	layer.	
3 Results	and	Discussion	
When	cultured	on	a	flat,	cell-adhesive	surface,	cells	typically	form	into	a	monolayer	cell	sheet	where	
the	 predominant	 interaction	 is	 the	 cell-substrate	 interaction	 (Pampaloni	 et	 al.	 2007).	 Conversely,	
seeding	of	cells	on	a	non-adhesive	surface	(e.g.,	agarose)	leads	to	the	predominant	formation	of	cell-
cell	and	cell-matrix	 interactions.	Moreover,	by	bringing	 these	cells	 into	close	contact	–	 typically	by	
seeding	them	in	non-adhesive	concave	shaped	wells	–	the	cells	will	be	much	more	likely	to	form	3-D	
tumor	spheroids	(Achilli	et	al.	2012;	Pampaloni	et	al.	2007;	Sutherland	1988),	as	illustrated	in	Error!	
Reference	source	not	found.a.	
Three	cell	lines	were	first	tested	for	spheroid	formation:	lung	cancer	cells	(A549),	brain	glioblastoma	
cancer	 cells	 (U87MG),	 and	 colon	 cancer	 cells	 (HCT-116).	Our	 results	 show	 that	 only	HCT-116	 cells	
formed	clear	spheroids	(cf.	Figure	S1),	consistent	with	other	successful	reports	of	HCT-116	spheroid	
culturing	(Karlsson	et	al.	2012;	Ravizza	et	al.	2009).	For	this	reason,	we	selected	this	cell	line	for	the	
current	study.	
3.1 Controlled	Tumor	Spheroid	Fabrication	and	Growth	Rates	
In	order	to	facilitate	our	experiments	using	tumor	spheroids	 in	a	microfluidic	device,	we	sought	to	
develop	a	production	scheme	that	would	allow	us	 to	produce	spheroids	of	a	 target	diameter	on	a	
given	day.	We	conceived	of	a	strategy	to	seed	a	variable	number	of	initial	cells	for	spheroid	growth,	
and	looked	at	the	time	required	for	each	condition	to	reach	target	spheroid	sizes.	We	hypothesized	
that	 the	 incubation	 time	 required	 for	 a	 spheroid	 to	 reach	 a	 target	 size	 would	 decrease	 with	 an	
increasing	number	of	initial	cells	loaded.	In	this	way,	we	could	achieve	a	staggered	growth	schedule	
of	tumor	spheroids.		
In	order	to	assess	the	optimal	cell	 seeding	and	 incubation	time	for	achieving	tumor	spheroids	of	a	
given	size	by	the	strategy	described	above,	spheroids	were	grown	in	microwells	coated	with	agarose	
and	seeded	with	an	 initial	number	of	 cells	per	well	 ranging	 from	250	 to	6000.	Figure	2b	plots	 the	
spheroid	diameter	obtained	from	optical	microscopy	as	a	function	of	incubation	time	from	days	4	to	
	
	
6	for	the	different	quantities	of	initially	seeded	cells.	The	diameters	observed	for	an	initial	seeding	of	
500	cells/well	are	consistent	with	HCT-116	spheroids	grown	using	an	automated	hanging	drop	method	
(Drewitz	et	al.	2011),	confirming	the	suitability	of	our	culture	setup.	The	solid	lines	are	linear	fits	of	
the	data	sets,	and	illustrate	the	linear	dependence	of	spheroid	size	on	incubation	time	for	different	
initial	quantities	of	seeded	cells	during	the	observation	period	(Drasdo	and	Höhme	2005;	Drewitz	et	
al.	2011;	Freyer	and	Sutherland	1985).	Prior	to	day	4,	there	is	a	lag	period	in	growth,	followed	by	an	
exponential	increase	in	the	spheroid	diameter	as	cells	begin	to	aggregate	into	a	spheroid.	From	day	4	
onward,	the	increase	in	spheroid	diameter	is	presumably	due	to	cell	division	(Drasdo	and	Höhme	2005).		
From	the	linear	fits	plotted	in	Error!	Reference	source	not	found.b,	we	can	estimate	the	time	necessary	
to	reach	our	target	spheroid	size.	Error!	Reference	source	not	found.c	plots	the	incubation	time	to	
achieve	spheroids	with	target	diameters	of	200,	400	and	600	µm.	The	error	bars	are	determined	from	
errors	associated	with	the	linear	fitting	in	Error!	Reference	source	not	found.b.	Using	these	data,	we	
were	able	to	achieve	a	supply	of	fresh	tumor	spheroids	with	the	target	diameter	each	day	to	facilitate	
our	experiments	using	the	tumor	spheroids	in	microfluidic	devices.	One	interesting	feature	of	these	
data	is	the	different	slope	of	the	linear	fit,	which	is	a	measure	of	spheroid	growth	rate	over	the	fitted	
date	range.	These	slopes	are	plotted	in	Figure	S2	as	a	function	of	initial	number	of	seeded	cells.	There	
is	a	clear	reduction	in	growth	rate	as	the	initial	number	of	seeded	cells	increase.	While	our	current	
study	did	not	allow	us	to	precisely	elucidate	the	mechanism	underlying	this	trend,	we	surmise	that	a	
reduction	in	quantity	of	nutrients	per	cell	with	increasing	initial	cell	count	(Drasdo	and	Höhme	2005)	
and	 stress	generated	on	cells	due	 to	 confinement	 in	 the	 spheroid	 (Ambrosi	and	Mollica	2002)	are	
primary,	coupled	factors.		
In	conducting	the	experiments	described	in	Error!	Reference	source	not	found.,	we	observed	that	not	
all	of	the	spheroids	formed	into	the	expected	spherical	shape,	and	instead	produced	many	smaller	
spheroids	or	misshaped	samples.	Examples	of	poorly	formed	spheroids	are	shown	in	Figure	S1	in	the	
Supporting	Information.	We	hypothesized	that	the	curvature	of	the	agarose	coating	was	not	sufficient	
to	promote	the	settling	of	the	tumor	cells	at	the	bottom	of	the	well.	Furthermore,	the	curvature	of	
the	agarose	surface	varies	 from	well	 to	well,	which	affects	 the	consistency	of	 the	spheroid	growth	
process.	 If	 the	 curvature	 of	 the	 coated	well	 increased,	 the	 cells	would	 settle	more	 quickly	 to	 the	
bottom	of	the	well	and	would	have	a	higher	probability	of	forming	a	single	spheroid	due	to	proximity.	
This	 concept	 is	 illustrated	 in	 Figure	 3a.	 To	 test	 this	 hypothesis,	 we	 used	 an	 alternative	 coating	
material—poly2-hydroxymethyl	 methacrylate)	 (PHEMA)—to	 coat	 curved	 microwells	 (Ivascu	 and	
Kubbies	2006).	The	PHEMA	coating	produced	a	much	thinner	film	than	the	agarose	deposited	 into	
flat-bottom	wells.	Since	the	spheroid	ultimately	forms	on	the	geometry	created	by	the	surface	coating,	
a	 thinner	 coating	better	preserves	 the	 geometry	of	 the	microwell.	As	 a	 result,	 the	PHEMA-coated	
curved	microwells	 presented	 the	 desired	 curvature	 to	 compare	 against	 the	 relatively	 flat	 coating	
produced	by	the	agarose.	Due	to	the	way	the	agarose	gel	is	deposited	into	the	microwell	and	solidifies,	
it	cannot	be	formed	into	thin	films	like	PHEMA,	thus	masking	the	curvature	of	the	microwell.		
The	results	of	spheroid	formation	in	both	well	types	under	identical	conditions	of	4.5	g/L	of	glucose	
(i.e.,	high	glucose	as	defined	below)	are	plotted	in	Figure	3b.	The	bars	indicate	the	number	of	properly	
formed	and	poorly	formed	spheroids	for	the	agarose-coated	wells	(green)	and	PHEMA-coated	wells	
(blue)	as	determined	by	visual	inspection.	The	agarose	data	show	that	after	3	days	of	incubation,	no	
spheroids	had	properly	 formed.	With	 increasing	 incubation	time,	 the	agarose	coated	wells	start	 to	
produce	 spheroids,	 and	 the	 fraction	 of	 these	 spheroids	 that	 are	 properly	 formed	 increases	 with	
incubation	time.	In	contrast,	the	PHEMA-coated	wells	produced	properly	formed	spheroids	by	day	3,	
and	 in	a	quantity	 comparable	 to	 longer	 incubation	 times.	We	conclude	 that	 the	greater	 curvature	
achieved	by	the	thinner,	more	uniform	coating	in	the	PHEMA-coated	wells	enhanced	the	production	
	
	
of	properly	formed	spheroids	by	promoting	the	initial	aggregation	of	the	cancer	cells	in	each	microwell	
into	a	single	spheroid.	
		
	
3.2 Manipulation	of	the	Tumor	Microenvironment	
With	a	protocol	for	producing	properly	formed	spheroids	established,	we	now	turn	our	attention	to	
the	microenvironment	in	the	tumor	spheroid.		Hypoxic	cells	have	been	reported	to	be	more	resistant	
to	certain	drugs	(Brown	2007)	and	necrotic	cell	regions	could	impede	drug	penetration	(Shannon	et	
al.	2003).	The	presence	of	hypoxic	cells	and	secondary	necrosis	is	a	direct	function	of	nutrient	supply.	
It	has	been	shown	that	under	typical	culture	conditions,	cell	constructs	of	sizes	larger	than	200	µm	
contain	hypoxic	cells,	and	that	necrotic	cores	exist	in	constructs	of	sizes	greater	than	500	µm	due	to	
the	presence	of	chemical	gradients	at	such	size	scales	(Hirschhaeuser	et	al.	2010).	We	targeted	tumor	
spheroids	 with	 a	 diameter	 of	 400	 µm	 in	 order	 to	 determine	 whether	 necrosis	 is	 present	 at	 this	
spheroid	size.	This	size	is	also	consistent	with	the	dimensions	of	a	recently	reported	microfluidic	device	
for	studying	uptake	of	nanoparticles	and	small	molecules	(Albanese	et	al.	2013b).	
Since	 microenvironmental	 conditions	 like	 hypoxic	 and	 necrotic	 cores	 are	 implicated	 in	 therapy	
resistance	in	tumors	(Cabral	et	al.	2011),	it	is	advantageous	if	the	presence	of	such	features	can	be	
manipulated	easily	in	an	in	vitro	tumor	model.	Since	hypoxic	and	necrotic	cores	result	from	gradients	
of	oxygen	and	nutrients	(e.g.,	glucose),	respectively,	varying	the	concentration	of	oxygen	and	nutrients	
affects	the	formation	and	extent	of	these	features	(Drasdo	and	Höhme	2005;	Freyer	and	Sutherland	
1986;	Jain	1999).	In	manipulating	the	presence	of	hypoxic	and	necrotic	cores,	it	is	important	that	the	
targeted	tumor	spheroid	size	can	be	attained	 for	 further	experimentation.	We	tested	whether	 the	
presence	of	a	necrotic	core	in	the	HCT-116	spheroids	could	be	manipulated	by	simply	changing	the	
glucose	concentration	 in	the	 incubation	media	from	4.5	g/L	to	1.0	g/L,	and	 if	 this	had	an	effect	on	
growth	rates	of	the	spheroids.	
As	a	starting	point,	histological	staining	and	immunostaining	were	performed	to	probe	the	density	of	
the	spheroids	and	presence	of	a	hypoxic	core.	Error!	Reference	source	not	 found.Error!	Reference	
source	 not	 found.	 shows	 characteristic	 images	 for	 both	 staining	 techniques	 for	 tumor	 spheroids	
produced	 under	 high	 glucose	 (4.5	 g/L)	 and	 low	 glucose	 (1.0	 g/L)	 conditions	 in	 agarose-coated	
microwells.	The	results	from	histological	staining	(left	column)	show	that	whether	cultured	in	low	or	
high	 glucose	 concentrations,	 spheroids	 formed	 nicely	 packed	 cellular	 structures	 (density	 80-90%).	
Furthermore,	for	similarly	sized	spheroids	grown	under	identical	conditions,	immunostaining	shows	
that	the	spheroids	contain	hypoxic	cells	at	an	average	depth	of	100	µm.	Since	the	level	of	oxygen	in	
the	 incubation	 environment	 remained	 constant	 for	 both	 glucose	 levels,	 it	 is	 expected	 that	 the	
presence	of	hypoxia	should	be	similar	for	both	spheroids.			
To	 determine	 whether	 the	 variation	 in	 glucose	 level	 had	 the	 desired	 effect	 of	 manipulating	 the	
presence	of	necrotic	cores,	spheroids	were	assayed	for	the	presence	of	 live	and	dead	cell	content,	
with	characteristic	results	shown	in	Error!	Reference	source	not	found.	for	spheroid	incubation	times	
of	5	days	and	7	days	at	high	and	low	glucose	concentration.	The	assay	stains	live	cells	green	and	dead	
cells	 red.	For	 the	high	glucose	content	 images	 (top	row),	 there	 is	a	perimeter	of	 living	cells	on	the	
spheroid,	while	dead	cells	appear	scattered	sparsely	 throughout	 the	spheroid.	 In	contrast,	 the	 low	
glucose	images	display	a	concentrated	core	of	dead	cells	in	the	spheroid,	indicating	the	formation	of	
a	necrotic	core.	For	both	glucose	concentrations,	there	is	a	large	region	of	apparently	quiescent	cells	
between	the	viable	rim	and	core	of	the	spheroids,	consistent	with	computer	simulation	results	(Drasdo	
	
	
and	Höhme	2005).	The	cited	computer	simulation	model	starts	from	a	single	cell	capable	of	dividing	
and	 incorporates	 mass	 transport	 and	 mechanical	 forces	 into	 the	 growing	 spheroid.	 The	 model	
reproduced	 successfully	 tumor	 spheroid	 growth	 data	 from	 prior	 literature	 reports	 (Freyer	 and	
Sutherland	1986),	and	 the	growth	data	presented	 in	Error!	Reference	source	not	 found.	exhibits	a	
linear	trend	as	predicted	by	the	computer	simulation	model.	
For	samples	prepared	in	high	and	low	glucose	concentrations,	analysis	of	spheroid	diameters	plotted	
in	Figure	S3	revealed	no	significant	difference	for	a	wide	range	of	initial	cell	seeding	values.	The	fact	
that	the	presence	of	the	necrotic	core	depends	on	the	glucose	concentration,	while	the	size	of	the	
spheroids	does	not	is	consistent	with	computer	simulations	of	tumor	spheroids	(Drasdo	and	Höhme	
2005).	 Furthermore,	 the	 necrotic	 core	 appears	 to	 grow	 in	 diameter	 and	 density	 with	 increasing	
incubation	time.	Although	the	necrotic	cores	shown	at	day	7	are	clearly	of	two	different	diameters,	
our	current	data	do	not	allow	us	 to	quantify	how	precisely	 the	size	of	 the	core	can	be	controlled.	
Nonetheless,	the	results	of	this	assay	show	that	the	presence	of	a	necrotic	core	depends	on	glucose	
concentration,	and	its	presence	can	be	manipulated	by	changing	glucose	concentration	and	incubation	
time	without	affecting	overall	spheroid	size.	
To	summarize	our	results	of	producing	an	in	vitro	tumor	model,	we	have	successfully	prepared	human	
colon	 cancer	 tumor	 spheroids.	 In	 doing	 so,	 we	 demonstrated	 the	 ability	 to	 tailor	 the	 size	 of	 the	
spheroids	by	varying	the	initial	number	of	seeded	cells	and	incubation	time.	The	spheroids	produced	
using	our	protocol	resulted	in	densely	packed	samples	that	exhibited	hypoxic	cores.	The	presence	of	
necrotic	cores	in	these	samples	could	be	manipulated	by	simply	changing	the	glucose	concentration	
in	the	incubation	medium,	which	had	no	significant	effect	on	the	spheroid	growth	rate,	as	predicted	
by	computer	simulations	(Drasdo	and	Höhme	2005).	With	a	suitable	tumor	model	created,	we	will	
now	focus	on	the	characterization	of	the	flow	field	around	a	tumor	spheroid	contained	in	a	microfluidic	
system	for	in	vitro	tumor	therapy	assessment.	
3.3 Micro-PIV	Characterization	of	Microfluidic	Device	with	Tumor	Spheroid	
We	fabricated	a	microfluidic	device	based	on	a	previously	reported	design	(Albanese	et	al.	2013b)	that	
mimics	 the	 flow	 of	 a	 branching	 capillary	 on	 a	 tumor	 mass	 (cf.	 Figure	 1b).	 In	 order	 for	 a	 tumor	
vasculature	mimic	to	be	physiologically	relevant,	 it	should	effectively	reproduce	the	flow	velocities	
present	in	in	vivo	vasculature.	Fluid	velocities	were	thus	measured	in	the	device	by	using	microparticle	
image	velocimetry	(micro-PIV),	which	tracks	the	movement	of	microparticles	to	characterize	the	flow	
field	of	 the	 fluid	carrying	 the	microparticles	 (cf.	Materials	and	Methods).	Figure	6a	and	6b	 show	a	
tumor	 spheroid	 contained	 within	 the	 observation	 chamber	 of	 the	 microfluidic	 device	 in	 a	 fluid	
containing	 fluorescent	 microparticles	 using	 brightfield	 and	 fluorescence	 microscopy,	 respectively.	
Micro-PIV	uses	a	series	of	 images	similar	to	that	shown	in	Figure	6b	 to	determine	the	velocity	and	
direction	of	the	fluid	flow.	Using	flow	rates	of	25	nL/s	and	125	nL/s	resulted	in	the	velocity	fields	shown	
in	Figure	6c	and	6d,	respectively,	which	are	plotted	using	the	same	color	scale.	The	measured	velocities	
were	found	to	be	in	the	physiological	range	of	mice	capillaries	(75-675	µm/s)	(Albanese	et	al.	2013b).		
An	additional	system	parameter	to	consider	is	the	shear	stress	on	the	tumor	spheroid,	which	should	
be	below	0.1	Pa	to	avoid	affect	cellular	behavior	(Dimmeler	et	al.	2015).	Shear	stress	can	be	estimated	
by	considering	both	cross	sections	on	the	left	and	right	of	the	seeded	spheroid	to	be	cylinders.	Shear	
stress	was	determined	by	applying	the	formula	describing	shear	stress	along	a	cylinder	wall:		𝜏 = 𝜇 4𝑄𝜋𝑟(	
	
	
	
Where	Q	is	the	volumetric	flow	rate	of	the	fluid,	µ	is	the	fluid	dynamic	viscosity	and	r	is	the	radius	of	
the	cylinder	used	to	model	the	space	between	the	tumor	spheroid	and	the	wall.		The	maximum	shear	
stress	on	the	tumor	mass	was	estimated	to	be	0.042,	which	is	below	the	0.1	Pa	minimum	threshold	
known	to	affect	cell	behavior	(Dimmeler	et	al.	2015)	
	
In	order	to	assess	the	profile	of	the	flow	velocity	around	the	spheroid,	the	velocities	from	Figure	6c	
and	6d	were	taken	along	lines	cut	at	either	x		=	1.6	mm	or	y	=	0.0	mm.	These	velocities	are	plotted	in	
Figure	7a	and	7b,	respectively	for	flow	rates	of	25	nL/s	(black	squares)	and	125	nL/s	(red	circles).	The	
profiles	are	similar	in	shape	for	both	flow	rates,	with	different	magnitudes	of	the	flow	velocities.	As	
seen	in	Figure	7a,	the	velocity	on	the	sides	of	the	spheroid	parallel	with	the	flow	direction	are	quite	
similar,	 consistent	with	 the	symmetry	of	 the	microfluidic	 system.	 In	contrast,	 the	velocities	on	 the	
sides	of	the	spheroid	perpendicular	to	the	flow	are	clearly	different,	with	the	“front”	of	the	spheroid	
experiencing	a	flow	rate	~	3x	greater	than	that	of	the	“back”	of	the	spheroid.		
With	 the	 heterogeneous	 velocity	 results	 of	 Figure	 7	 in	 mind,	 we	 assessed	 the	 accumulation	 and	
penetration	of	fluorescent	polystyrene	nanoparticles	with	diameters	of	either	20	nm	or	50	nm	in	the	
tumor	 spheroid.	 Nanoparticle	 size	 was	 measured	 by	 dynamic	 light	 scattering	 under	 observation	
conditions	(identical	imaging	temperature	and	identical	imaging	buffer)	in	order	to	check	nanoparticle	
size	 and	 detect	 any	 particle	 aggregation.	 No	 particle	 aggregation	was	 observed	 over	 a	 60	minute	
timescale	(data	not	shown)	and	the	size	range	measured	by	dynamic	light	scattering	was	consistent	
with	that	expected	(cf.	Figure	S1).	
The	effect	of	the	asymmetric	velocity	profile	observed	in	Figure	7b	was	measured	by	integrating	the	
intensity	of	the	fluorescence	over	a	15o	arc	on	the	front	center	and	back	center	of	spheroids	exposed	
to	20	and	50	nm	particles	at	125	nL/s	(cf.	Figure	S2).	The	ratio	of	the	front	side	intensity	to	back	side	
intensity	is	displayed	in	Table	1,	with	both	the	20	nm	and	50	nm	particles	showing	a	higher	intensity	
in	the	front	than	the	back	(i.e.,	ratio	is	greater	than	unity).	While	our	data	can	only	provide	a	
preliminary	conclusion,	if	this	in	vitro	result	mimics	in	vivo	performance,	this	geometrical	effect	in	
particle	uptake	highlights	an	additional	challenge	in	effectively	targeting	tumors	with	nanoparticles.	
Table	1	Relative	fluorescence	intensity	of	the	front	side	and	back	side	of	tumor	spheroids.	
Particle	Diameter	 Intensity	Ratio	of		
Front	Side	to	Back	Side	
20	nm	 1.33	
50	nm	 1.19	
	
We	next	analyzed	the	penetration	of	20	nm	nanoparticles	into	the	tumor	spheroids	over	a	period	of	
60	minutes,	the	results	of	which	are	plotted	in	Figure	8a.	The	fluorescence	intensity	within	the	
spheroid	was	averaged	over	10	µm	thick	layers	down	to	a	total	depth	of	50	µm.	A	thickness	of	10	µm	
was	chosen	because	it	is	the	mean	diameter	of	the	cells	forming	the	spheroids	as	assessed	by	
microscopy	images.	The	data	sets	are	grouped	in	terms	of	“cell	layers”	(i.e.,	10	µm	increments).	For	
all	depths,	there	is	an	increase	in	intensity	with	exposure	time,	followed	by	a	plateau	after	≈45	
minutes.	While	the	first	20	µm	of	depth	in	the	spheroid	has	essentially	the	same	fluorescence	
intensity,	and	thus	concentration	of	nanoparticles,	subsequent	depths	exhibit	markedly	lower	
fluorescence.	Since	the	fluorescence	intensity	has	plateaued	by	60	minutes,	this	time	point	was	
chosen	to	analyze	the	effect	of	flow	rate	and	particle	diameter	on	nanoparticle	penetration.	
	
	
The	results	in	Error!	Reference	source	not	found.b	plot	fluorescence	intensity	for	each	10	µm	thick	
slab	extending	into	the	spheroid	exposed	to	20	and	50	nm	particles	at	125	nL/s	flow	rate	(black	
squares	and	red	circles,	respectively),	and	20	nm	particles	with	no	flow	(open	square).	There	is	a	
clear	increase	in	fluorescence	intensity	in	the	first	20	µm	of	depth	for	the	20	nm	particles	under	flow	
compared	to	the	50	nm	particles.	However,	this	difference	rapidly	decreases	beyond	20	µm	of	
depth.	Without	flow,	the	20	nm	particles	show	a	similar	profile	to	that	observed	for	the	50	nm	
particles	with	flow.	While	this	overlap	is	probably	coincidental,	it	does	illustrate	the	significant	effect	
convection	has	on	nanoparticle	uptake.	
These	results	illustrate	an	overall	poor	penetration	capacity	of	the	polystyrene	nanoparticles	into	our	
in	vitro	tumor	mimic,	and	is	characteristics	of	the	observation	that	nanoparticles	of	the	size	used	in	
this	study	cannot	penetrate	the	interstitial	space	between	tumor	cells	(Cabral	et	al.	2011;	Huang	et	al.	
2012;	Huo	et	al.	2013;	Perrault	et	al.	2009;	Wong	et	al.	2011).	This	result	is	in	spite	of	the	fact	that	the	
exterior	of	the	spheroid	appears	to	saturate	with	nanoparticles,	as	seen	in	Error!	Reference	source	
not	 found.a.	 Even	 in	 this	 ideal	 simulation,	 where	 a	 continuous	 flow	 of	 nanoparticles	 was	 applied	
without	 flushing,	 the	 smallest	 size	 nanoparticle	 (20nm)	 barely	 managed	 to	 penetrate	 50	 µm	 in	
distance	 into	the	tumor	mass.	This	distance	 is	still	 far	 from	the	100	µm	distance	required	to	reach	
hypoxic	cells,	let	alone	the	200-250	µm	threshold	where	central	necrosis	is	found.	With	intercapillary	
distance	in	tumor	tissue	ranging	(in	certain	cases)	to	several	hundred	microns,	these	results	underline	
the	need	to	design	highly	penetrating	nanoparticles	by	taking	advantage	of	particle	size	and	surface	
chemistry,	or	using	a	different	delivery	strategy.	
4 Conclusion	
We	have	successfully	prepared	human	colon	cancer	tumor	spheroids	from	HCT-116	cells.	In	doing	so,	
we	demonstrated	the	ability	to	tailor	the	size	of	the	spheroids	by	varying	the	initial	number	of	
seeded	cells	and	incubation	time.	The	spheroids	produced	using	our	protocol	resulted	in	densely	
packed	samples	that	exhibited	hypoxic	cores.	The	presence	of	necrotic	cores	in	these	samples	could	
be	manipulated	by	simply	changing	the	glucose	concentration	in	the	incubation	medium,	which	had	
no	significant	effect	on	the	spheroid	growth	rate,	both	verified	by	our	experiments	and	predicted	by	
a	computer	simulation	model	(Drasdo	and	Höhme	2005).	We	further	examined	the	flow	profile	
around	a	tumor	spheroid	contained	in	a	recently	described	microfluidic	device	using	micro-PIV.	This	
flow	profile	correlated	with	a	heterogeneous	accumulation	of	fluorescent	polystyrene	nanoparticles	
at	the	perimeter	of	the	tumor	spheroid.	The	further	penetration	of	these	nanoparticles	into	the	
tumor	spheroid	exhibited	a	dependence	on	nanoparticle	size	and	the	flow	rate	of	the	surrounding	
media,	consistent	with	observation	for	other	nanoparticle	systems.	Going	forward,	this	platform	will	
allow	evaluation	of	therapeutic	nanoparticles	and	other	tumor	therapies	in	lab	settings,	while	
covering	a	broad	range	of	tumor	microenvironments	to	illustrate	the	effect	microenvironment	has	
on	tumor	therapies.	
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	Fig.	1	(a)	Tumors	can	receive	blood	borne	nutrients	through	the	vasculature	system.		This	same	mode	of	delivery	can	
be	used	to	expose	in	vivo	tumors	to	pharmaceutical	agents.		(b)	The	schematic	shows	a	microfluidic	device	designed	
to	replicate	the	in	vivo	blood	vessel	flow.		The	channels	outlined	in	blue	had	thickness	of	380	µm	and	widths	of	600	
µm.		These	dimensions	were	chosen	to	mimic	dimensions	within	the	human	body.		The	inlet	channel	expands	to	a	
width	of	1200	µm	to	create	an	imaging	chamber	to	observe	spheroid	responses	to	materials	carried	within	the	flow	
channel	(e.g.,	nanoparticles	or	pharmaceutical	agents).		The	red,	circular	region	is	a	dam	25	µm	in	thickness	to	enable	
sequestration	of	the	spheroid	in	the	imaging	chamber.		An	optical	microscopy	image	of	a	tumor	spheroid	contained	
within	the	imaging	chamber	of	the	microfluidic	device	is	superimposed	over	the	device	schematic.	
	 	
	Fig.	2	(a)		Schematic	showing	the	method	of	producing	tumor	spheroids	by	incubating	cancer	cells	in	agarose-coated	
cylindrical,	flat-bottom	wells.		At	sufficiently	long	incubation	times,	the	cancer	cells	spontaneously	form	into	tumor	
spheroids.		The	inset	shows	a	brightfield	microscopy	image	of	a	properly	shaped	(i.e.,	spherical)	tumor	spheroid.		(b)		
Tumor	spheroid	diameter	plotted	as	a	function	of	incubation	time	for	different	initial	numbers	of	seeded	cells.		The	
solid	lines	are	linear	fits	to	the	data.		(c)		Required	incubation	time	for	a	given	number	of	cells	seeded	initially	into	a	
microwell	for	target	tumor	spheroid	diameters	of	200	µm	(red	circles),	400	µm	(black	squares)	and	600	µm	(blue	
triangles).	The	solid	lines	are	linear	fits	of	each	data	set	plotted	on	the	log	scale.	The	fits	had	R2	values	of	0.99	(red),	
0.97	(black)	and	0.99	(blue).	Images	not	drawn	to	scale.	
	 	
	Fig.	3	(a)		Possible	end	results	for	culturing	cancer	cells	in	an	agarose-coated	well	(top)	and	PHEMA-coated	round	
bottom	 well	 (bottom).	 	 The	 thin	 film	 of	 PHEMA	 preserves	 the	 shape	 of	 the	 round	 bottom	 well,	 resulting	 in	
sedimentation	of	cells	at	the	bottom	of	the	well	and	rapid	formation	of	properly	shaped,	spherical	spheroids.		(b)		
Comparison	of	spheroid	shape	for	agarose-coated	wells	(green)	and	PHEMA	coated	wells	(blue).	 	Agarose-coated	
wells	 initially	 form	 spheroids	 that	 are	poorly	 shaped,	which	 then	grow	 into	well	 formed	 spheroids.	 	 In	 contrast,	
PHEMA-coated	wells	rapidly	form	properly	formed	spheroids.	The	error	bars	correspond	to	the	standard	deviation	
of	two	separate	experiments.	
	 	
	Fig.	4	Spheroids	cultured	in	high	(a,	b)	and	low	(c,	d)	glucose	concentration	conditions	were	analyzed	by	histological	
staining	(a,	c)	to	reveal	cell	packing	and	by	immunostaining	to	reveal	hypoxic	regions	(b	,d).		Immunostaining	enables	
simultaneous	visualization	of	cell	nuclei	(blue)	and	hypoxic	regions	(green).	All	spheroids	were	harvested	after	5	days	
of	culture	except	for	the	high	glucose	immunostained	sample	which	was	cultured	for	7	days.	
	 	
	Fig.	5	Midplane	captures	of	proliferating	cells	(green)	and	dead	cells	(red)	in	spheroids	cultured	for	5	days	(left)	and	
7	days	(right)	at	high	glucose	(top)	and	low	glucose	(bottom)	conditions.	The	scale	bar	corresponds	to	length	scales	
for	both	high	and	low	glucose	images.	
	 	
	Fig.	6	(a)	Phase	contrast	image	of	spheroid	sequestered	in	the	device	imaging	chamber.		(b)	Raw	data	collected	
from	the	micro-PIV	showing	fluorescent	microparticles	and	spheroid	(outlined	by	the	white	line)	in	the	device	
imaging	chamber.	(c,	d)	Fluid	velocity	inside	device	in	the	presence	of	a	cancer	cell	spheroid	determined	by	the	
micro-PIV	for	flow	rates	of	25	nl/s	(c)	and	125	nl/s	(d).	The	dashed	black	line	in	panel	d	corresponds	to	the	data	
shown	in	Figure	7.	
	 	
	Fig.	7		Line	cuts	taken	from	the	data	in	Fig.	6d	for	volumetric	flow	rates	of	25	nL/s	(black)	and	125	nL/s	(red).		(a)		
Cut	made	along	the	x-axis	at	~1.6	mm	(i.e.,	middle	of	the	spheroid)	showing	the	velocity	profile	along	the	y-axis	for	
both	volumetric	flow	rates.		(b)		Cut	made	along	the	y-axis	at	~-0.5	mm	(i.e.,	middle	of	the	spheroid)	showing	the	
velocity	profile	along	the	x-axis	for	both	volumetric	flow	rates.		While	the	y-axis	velocity	profile	shows	a	
symmetrical	profile	about	the	spheroid	for	both	flow	rates,	the	x-axis	velocity	profile	shows	a	higher	velocity	at	the	
front	of	the	spheroid	compared	to	the	back	of	the	spheroid	relative	to	the	direction	of	flow.	
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	Fig.	8	(a)	Fluorescence	intensity	of	20	nm	nanoparticles	for	different	depths	in	a	tumor	spheroid	as	a	function	of	
exposure	time.	(b)	Fluorescence	intensity	in	tumor	spheroids	exposed	to	fluorescent	nanoparticles	with	diameters	
of	20	nm	(black,	filled	squares)	or	50	nm	(red,	filled	circles)	at	125	nL/s,	or	20	nm	with	no	flow	(black,	open	
squares).		Cell	layer	was	calculated	by	assuming	the	average	cell	is	10	µm	in	diameter,	thus	the	first	cell	layer	
represents	the	first	10	µm	from	the	perimeter	of	the	spheroid	inward.	
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